BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yuan Y, Du Y, Wang L, Liu X. The value of endothelin receptor type B promoter methylation as a biomarker for the risk assessment and diagnosis of prostate cancer: A meta-analysis. Pathol Res Pract 2020;216:152796. [PMID: 31926772 DOI: 10.1016/j.prp.2019.152796] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
Number Citing Articles
1 Tu J, Chen S, Wu S, Wu T, Fan R, Kuang Z. Tumor DNA Methylation Profiles Enable Diagnosis, Prognosis Prediction, and Screening for Cervical Cancer. IJGM 2022;Volume 15:5809-21. [DOI: 10.2147/ijgm.s352373] [Reference Citation Analysis]
2 Liu Z, Zhong J, Cai C, Lu J, Wu W, Zeng G. Immune-related biomarker risk score predicts prognosis in prostate cancer. Aging (Albany NY) 2020;12:22776-93. [PMID: 33197890 DOI: 10.18632/aging.103921] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]